Ignite Creation Date:
2024-05-06 @ 5:25 PM
Last Modification Date:
2024-10-26 @ 2:29 PM
Study NCT ID:
NCT05308004
Status:
COMPLETED
Last Update Posted:
2024-01-18
First Post:
2022-03-24
Brief Title:
Palliative Care for Persons With ADRD and CI in SNF
Sponsor:
University of Maryland Baltimore
Organization:
University of Maryland Baltimore
Study Overview
Official Title:
Palliative Care Consultations for Persons With Alzheimers Disease and Related Dementia and Cognitive Impairment in the Medicare Skilled Nursing Facility SNF Setting
Status:
COMPLETED
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Alzheimers disease and related dementias ADRD are serious life limiting illnesses with no known cure Dementia is the fifth-leading cause of death in older adults and the majority of people with advanced dementia die in nursing homes NHs Miller et al reported that 40 of US NH residents dying with advanced dementia received Skilled Nursing Facility SNF care in the last 90 days of life and receipt of this care was associated significantly with poorer end-of-life outcomes including a higher risk of dying in a hospital compared to decedents with no SNF care SNF care is a Medicare post-acute rehabilitation service delivered in NHs focused on intense rehabilitation andor aggressive disease-modifying therapies Regardless of life expectancy use of SNF care precludes access to Hospice services Palliative care PC offers an evidence-based alternative
Detailed Description:
In this pragmatic clinical trial broadcast notification will be utilized to inform all newly admitted patients at each study site of their participation in this trial During the admission process potential subjects will be provided with a 1-page summary sheet Broadcast notification detailing their participation in this study that will include contact information for the study team should the subject or their LARsurrogate decision maker elect to opt-out of participating
Baseline data will be collected virtually via telephone by asking each subject or if unable to respond their surrogate decision maker to complete the Patient Outcomes Scale POSv2 the Satisfaction With Care at the End of Life in Dementia SWC-EOLD and the Symptom Management at the End of Life in Dementia SM-EOLD
Between 14 days and 21 days after the baseline POSv2 SW-EOLD and the SM-EOLD are administered all subjects or if unable to respond their surrogate decision maker will be asked to complete the POSv2 SW-EOLD and the SM-EOLD again virtually via telephone The POSv2 SW-EOLD and the SM-EOLD will be given a total of two times to those in the INTERVENTION and CONTROL groups at baseline and follow up 14-21 days later
Deidentified subject demographics will be collected on all participants in the following way Study team members will review subjects medical records and enter de-identified data into a Research Electronic Data Capture REDCap database Acts staff assists with the study teams access to subjects medical record
Palliative Care Encounter Trained provider will discuss illness trajectories establish and communicate patient-directed goals that guide health care decisions identify and treat illness-related symptoms and identify psycho-spiritual needs and approaches to mitigate suffering
Baseline data will be collected virtually via telephone by asking each subject or if unable to respond their surrogate decision maker to complete the Patient Outcomes Scale POSv2 the Satisfaction With Care at the End of Life in Dementia SWC-EOLD and the Symptom Management at the End of Life in Dementia SM-EOLD
Between 14 days and 21 days after the baseline POSv2 SW-EOLD and the SM-EOLD are administered all subjects or if unable to respond their surrogate decision maker will be asked to complete the POSv2 SW-EOLD and the SM-EOLD again virtually via telephone The POSv2 SW-EOLD and the SM-EOLD will be given a total of two times to those in the INTERVENTION and CONTROL groups at baseline and follow up 14-21 days later
Deidentified subject demographics will be collected on all participants in the following way Study team members will review subjects medical records and enter de-identified data into a Research Electronic Data Capture REDCap database Acts staff assists with the study teams access to subjects medical record
Palliative Care Encounter Trained provider will discuss illness trajectories establish and communicate patient-directed goals that guide health care decisions identify and treat illness-related symptoms and identify psycho-spiritual needs and approaches to mitigate suffering
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None